Martell Diagnostic Laboratories Company
High-affinity tests that monitor the use of onco-therapeutics that support cancer treatment de-escalation to achieve better outcomes with less drug, less cost and improved quality of life.
Metastatic breast cancer is now considered a chronic condition with effective treatments that in many ways allow women to lead a normal or near normal life. Yet, many women live with the fear that their cancer may no longer be responding to medication or the disease has flared in advance of overt clinical symptoms. They believe that a simple bloodtest can effectively monitor medication and help detect recurrences of HER2 tumors. Plus, monitoring helps to reduce anxiety. Therein lies the value of monitoring serum HER2 for women with metastatic HER2 tumors--the possibility of real-time, actionable information and additional peace of mind.
Metastatic breast cancer is now considered a chronic condition with effective treatments that in many ways allow women to lead a normal or near normal life. Yet, many women live with the fear that their cancer may no longer be responding to medication or the disease has flared in advance of overt clinical symptoms. They believe that a simple bloodtest can effectively monitor medication and help detect recurrences of HER2 tumors. Plus, monitoring helps to reduce anxiety. Therein lies the value of monitoring serum HER2 for women with metastatic HER2 tumors--the possibility of real-time, actionable information and additional peace of mind.
Industry:
General Healthcare
Headquarters:
Rockville, Minnesota, United States
Founded Date:
01-01-2008
Employees Number:
11-50
Funding Status:
Seed
Total Funding:
$365,000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2018-06-12
Last Funding Type:
Seed
Register and Claim Ownership